An Open-Label Phase 3 Study to Assess the Immunogenicity and Safety of a Vero Cell-Derived Trivalent Seasonal Influenza Vaccine, Strain Composition 2009/2010, in an Adult and Elderly Population
Phase of Trial: Phase III
Latest Information Update: 13 Oct 2015
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Baxter Healthcare Corporation
- 08 Oct 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
- 08 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Jul 2009 New trial record